XTalks

JANUARY 20, 2025

Among these, mergers and acquisitions (M&As) have played a pivotal role in reshaping the industry landscape, enabling companies to bolster their portfolios, enhance R&D capabilities and expand their global market reach. While the deal required regulatory divestitures, including the sale of Otezla (apremilast) to Amgen for $13.4

Marketing 104

Marketing Botox Life Science Pharma Companies 104

pharmaphorum

SEPTEMBER 11, 2020

Prior to the $63 billion takeover by AbbVie, Allergan’s biggest product was botulinum toxin product Botox, best known as a wrinkle and migraine treatment, and that headed a sizeable medical aesthetics portfolio at the company which also included dermal filler products like Juvederm.

Botox 119

Botox Filler Production Marketing 119

pharmaphorum

NOVEMBER 4, 2020

Novartis recorded Aimovig sales of $108 million in the first nine months of 2020, a rise of 44% on the same period of 2019, and says it is the most prescribed drug in the CGRP inhibitor class with 480,000 patients using it worldwide. Novartis and Amgen are however locked in a legal battle over marketing rights to the drug.

Botox 96

Botox Sales Doctors Doctor 96

XTalks

NOVEMBER 1, 2024

The neurology drug market continues to be dynamic with novel treatments that cater to a broad range of neurological and psychiatric conditions. In 2024, several blockbuster neurology medications are set to lead the market, capturing the attention of healthcare professionals, investors and patients alike.

FDA Approval 85

FDA Approval Drugs Botox Sales 85

pharmaphorum

NOVEMBER 18, 2020

The decision means that with two CGRP antibodies now cleared for migraine prevention, the first drug in the class to be approved in Europe – Novartis’ Aimovig (erenumab) – has fallen further behind its rivals in getting access to the UK market.

Sales 96

Sales Botox Antibody Drugs 96

pharmaphorum

NOVEMBER 18, 2020

The decision means that with two CGRP antibodies now cleared for migraine prevention, the first drug in the class to be approved in Europe – Novartis’ Aimovig (erenumab) – has fallen further behind its rivals in getting access to the UK market.

Sales 94

Sales Botox Antibody Drugs 94

pharmaphorum

SEPTEMBER 29, 2021

AbbVie has added a third drug to its arsenal in the crowded migraine market, getting FDA approval for Qulipta – its once-daily oral preventive therapy for episodic migraines. AbbVie acquired Qulipta in 2020 as part of its $63 billion takeover of Allergan, which also brought in Botox and Ubrelvy.

Botox 52

Botox Sales Marketing FDA Approval 52